aetherAI

Genuinely dual: aetherSlide is an image management platform, the infrastructure layer, while aetherAI Hema and the lymph node detector are diagnostic algorithms. The 2026 FDA and IVDR clearances cover the PLATFORM, which triggers the same principle applied to Indica Labs and ModMed, since a laboratory could deploy the cleared platform and run no AI at all. Graded B rather than C because unlike those precedents the company also builds its own substantive algorithms, notably a bone marrow differential system it describes as a world first, so the AI is not merely a layer bolted onto acquired infrastructure.

Assistive across the portfolio. The lymph node product detects, classifies, and quantifies metastases for pathologist review, and the hematology product produces differential counts a hematopathologist verifies. Bone marrow differential counting is a task where the manual alternative is a human counting hundreds of cells under a microscope, so automation here displaces tedium rather than judgment, and the pathologist retains interpretation. No published detail on confidence thresholds or when cases route back for manual review was located.

Training scale is disclosed for the hematology product, more than one million curated cells producing 15 subtype differential counts at a reported 94 percent accuracy, which is a specific and checkable claim. But that accuracy figure is not broken out by subtype, and rare cell types are precisely where differential counting is hardest and where a headline average conceals weakness. Equivalent performance data for the lymph node detector and the platform was not located, and the founder's academic publication record in venues including Nature Communications is corporate credibility rather than product validation.

Adoption at named major institutions is the strongest signal: deployment of the platform across four Chang Gung Memorial Hospital branches, Taiwan's largest medical centre, plus development collaborations since 2018 with National Taiwan University Hospital and Chi Mei Medical Center, and a strategic partnership with Novartis Taiwan on myeloproliferative neoplasm diagnosis. Independent survey work on public evidence for digital pathology AI indexes the lymph node product with minimal associated publication record. No peer reviewed validation study specific to these products was located, so this rests on institutional adoption rather than published performance.

No specific PHI handling or data governance framework was located in the materials reviewed.

No HIPAA or BAA commitment was located. Now holding FDA clearance for the platform and pursuing global expansion, a Taiwan headquartered vendor selling into US laboratories would need business associate terms established directly.

No SOC 2, ISO 27001, or equivalent attestation and no trust center were located in the materials reviewed.

A meaningful 2026 milestone: the digital pathology platform secured both FDA clearance and IVDR certification, which is a harder combination than either alone and puts the company alongside PathAI and Indica Labs as platforms authorized on both sides of the Atlantic. Taiwan FDA clearance for aetherSlide came earlier. The algorithm portfolio is less advanced regulatorily, with independent survey work indexing the lymph node product as CE-IVD General under the older IVDD directive rather than IVDR, the same distinction flagged against Visiopharm, Owkin Dx, and DoMore. Graded B rather than A because the strongest authorization covers the platform while the diagnostic algorithms sit at a lower regulatory tier.

No governance framework, monitoring commitment, or subgroup performance analysis was located. The gap has a specific edge here: models developed and validated predominantly on Taiwanese patient populations now carry FDA clearance for a global market, and no evidence addressing performance consistency across populations was published.

The platform is the integration story, functioning as an image management system that hosts diagnostic algorithms and connects to scanning infrastructure, including a fully automated slide scanning solution built with Techman Robot and Hamamatsu Photonics that pairs a collaborative robot with scanning hardware. That automation of the physical slide handling step is unusual, since most pathology AI vendors assume slides arrive already digitized. Laboratory and image environment integration; no EHR integration claimed. No published connector list was located.

No hosting, tenancy, or data residency terms were located in the materials reviewed.

No pricing is published. The company has applied to list on the Taiwan Innovation Board, which if completed would bring exchange level financial disclosure and give buyers visibility into vendor stability comparable to Lunit, Aiforia, and VUNO. Backing from Quanta Computer, a major contract manufacturer, and Cathay Venture indicates capital depth. Nothing on per case, per model, or platform licensing cost was located.

Broader than most pathology vendors because it spans two distinct domains rather than one tumour type. Anatomic pathology is covered via the platform and the gastric cancer lymph node detector, while hematopathology is covered by the bone marrow differential system, a genuinely underserved area where far fewer AI products exist than in solid tumour histopathology. Biopharma enterprise services extend the customer base beyond hospitals. Coverage is strongest in Asia, with global expansion following the 2026 clearances.